The impact of three single-nucleotide polymorphisms in eotaxin (SCYA11) gene promoter (-426C>T and -384A>G) and first exon (67G>A) and recently described hexanucleotide (GAAGGA)(n) 10.9 kb upstream on coronary atherosclerosis was investigated. Elective coronary angiography of 1050 consecutive subjects was performed. All patients were genotyped for the three SNPs. In a subset of the first 472 samples, the number of (GAAGGA)(n) repetitions was determined. For further evaluation, short and long variants were distinguished; the borderline corresponded with the median value of all alleles: ≤8 repetitions were considered as short sequence, ≥9 repetitions as long. Patients with bronchial asthma or insignificant atherosclerosis were excluded; the remaining group of 933 subjects was further investigated. Patients were grouped according to the form of CAD (ACS vs. stable angina) and the number of diseased vessels. The GG variant of 67 G>A polymorphism was associated with acute form of CAD compared to stable angina (p=0.0011, p(corr.)=0.013). The number of (GAAGGA)(n) repetitions in our set of patients ranged from 3 to 12. There were no subjects with 4 or 5 repetitions. The frequency of short repetition alleles increased with the number of affected vessels (1 vs. 3 diseased vessels: p=0.0043, p(corr)=0.034). In our study, the (GAAGGA)(n) hexanucleotide was associated with the severity of CAD. The 67 GG was associated with acute form of CAD. None of the two SNPs in eotaxin promoter had any relation to CAD. The number of (GAAGGA)(n) repetitions can thus be a novel genetic marker of the extent of CAD.

Department of Pathophysiology Faculty of Medicine Masaryk University Brno Czech Republic

See more in PubMed

Hum Genet. 2005 Nov;118(2):287-94 PubMed

Curr Cardiol Rep. 2010 Jul;12(4):338-43 PubMed

Biochem Biophys Res Commun. 1993 Dec 30;197(3):1167-72 PubMed

Stat Appl Genet Mol Biol. 2009;8:Article32 PubMed

J Allergy Clin Immunol. 2006 Feb;117(2):298-305 PubMed

Science. 1997 Sep 26;277(5334):2005-7 PubMed

Circulation. 2004 Aug 24;110(8):928-33 PubMed

J Immunol. 2002 Sep 1;169(5):2712-8 PubMed

J Clin Invest. 1996 Feb 1;97(3):604-12 PubMed

Atherosclerosis. 2006 Dec;189(2):458-63 PubMed

Physiol Rev. 2006 Apr;86(2):515-81 PubMed

Circulation. 2000 Oct 31;102(18):2185-9 PubMed

Circ Res. 1995 Sep;77(3):445-65 PubMed

Eur Heart J. 2010 Jun;31(12):1457-69 PubMed

J Med Genet. 2007 Jun;44(6):397-403 PubMed

Biochemistry. 1994 May 17;33(19):5674-81 PubMed

Cytokine. 2012 Feb;57(2):251-7 PubMed

Pathol Biol (Paris). 2006 Sep;54(7):375-86 PubMed

Clin Exp Dermatol. 2008 May;33(3):316-21 PubMed

Arterioscler Thromb Vasc Biol. 2011 May;31(5):969-79 PubMed

Atherosclerosis. 2006 May;186(1):140-5 PubMed

Physiol Genomics. 2007 Nov 14;31(3):402-9 PubMed

Int J Cardiol. 2001 Aug;80(1):55-60 PubMed

Br Heart J. 1993 Jan;69(1 Suppl):S38-41 PubMed

Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1510-20 PubMed

J Investig Med. 2006 Dec;54(8):446-54 PubMed

Lab Invest. 1988 Mar;58(3):249-61 PubMed

Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1211-6 PubMed

Proc Natl Acad Sci U S A. 1959 Jul;45(7):984-9 PubMed

Neurology. 2011 Sep 20;77(12):1165-73 PubMed

Genomics. 1997 May 1;41(3):471-6 PubMed

Atherosclerosis. 2005 Dec;183(2):268-74 PubMed

Pharmacol Ther. 2011 Sep;131(3):255-68 PubMed

Biochem Biophys Res Commun. 1997 Feb 13;231(2):365-8 PubMed

EMBO J. 1992 Oct;11(10):3777-86 PubMed

Atherosclerosis. 2004 Jul;175(1):91-4 PubMed

Genes Immun. 2001 Dec;2(8):461-3 PubMed

Ann N Y Acad Sci. 1985;454:115-20 PubMed

J Immunol. 2005 Feb 1;174(3):1525-31 PubMed

Polymorphism rs7079 in miR-31/-584 Binding Site in Angiotensinogen Gene Associates with Earlier Onset of Coronary Artery Disease in Central European Population

The Relation between eNOS -786 C/T, 4 a/b, MMP-13 rs640198 G/T, Eotaxin 426 C/T, -384 A/G, and 67 G/A Polymorphisms and Long-Term Outcome in Patients with Coronary Artery Disease